The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients

European Journal of Clinical Pharmacology

Volumn 65, Issue 7, 2009, Pages 659-665

  Gustafsson, Finn ^b   Barth, David ^a   Delgado, Diego H ^a   Nsouli, Meerna ^a   Sheedy, Jill ^a   Ross, Heather J ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b University of Copenhagen   (Denmark)

Author keywords

Calcineurin inhibitors; Proliferation signal inhibitors; Rejection; Renal failure

Indexed keywords

ATORVASTATIN; BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PRAVASTATIN; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOCYTE; MALE; PRIORITY JOURNAL; RECIPIENT; TIME TO MAXIMUM PLASMA CONCENTRATION;

AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 67649124252     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0663-2     Document Type: Article

References (24)

1. DO Taylor LB Edwards MM Boucek EP Trulock P Aurora J Christie F Dobbels AO Rahmel BM Keck MI Hertz 2007 Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007 J Heart Lung Transplant 26 769 781 (Pubitemid 47199081)
2. A Alam K Badovinac F Ivis L Trpeski M Cantarovich 2007 The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR) Am J Transplant 7 461 465 (Pubitemid 46096341)
3. CE Angermann S Stork A Costard-Jackle TJ Dengler U Siebert G Tenderich A Rahmel ER Schwarz H Nagele FM Wagner B Haaff K Pethig 2004 Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients-the IMPROVED multi-centre study Eur Heart J 25 1626 1634 (Pubitemid 39209283)
4. D Grant N Kneteman J Tchervenkov A Roy G Murphy A Tan L Hendricks N Guilbault G Levy 1999 Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8) Transplantation 67 1133 1137 (Pubitemid 29205575)
5. M Cantarovich JG Besner JS Barkun E Elstein R Loertscher 1998 Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy Clin Transplant 12 243 249 (Pubitemid 28269248)
6. DH Delgado V Rao J Hamel S Miriuka RJ Cusimano HJ Ross 2005 Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes J Heart Lung Transplant 24 1343 1346 (Pubitemid 41247820)
7. M Cantarovich E Elstein B de Varennes JS Barkun 1999 Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients Transplantation 68 1839 1842 (Pubitemid 30027333)
8. M Cantarovich H Ross JM Arizon MA Gomez L Straatman J Orus L Alonso-Pulpon BD Molina S Wang E Lage MG Crespo N Manito J Howlett H Haddad 2008 Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction Transplantation 85 992 999 (Pubitemid 351543163)
9. HJ Eisen EM Tuzcu R Dorent J Kobashigawa D Mancini HA Valantine-von Kaeppler RC Starling K Sorensen M Hummel JM Lind KH Abeywickrama P Bernhardt 2003 Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 847 858 (Pubitemid 37025404)
10. F Gustafsson HJ Ross MS Delgado G Bernabeo DH Delgado 2007 Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction J Heart Lung Transplant 26 998 1003 (Pubitemid 47494663)
11. H Ross P Pflugfelder H Haddad M Cantarovich M White A Ignaszewski J Howlett M Vaillancourt R Dorent JR Burton 2008 Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients J Heart Lung Transplant 27 197 202 (Pubitemid 351221047)
12. BD Kahan RL Wong C Carter SH Katz J Von Fellenberg CT Van Buren S Appel-Dingemanse 1999 A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients Transplantation 68 1100 1106 (Pubitemid 29517697)
13. H Podder SM Stepkowski KL Napoli J Clark RR Verani TC Chou BD Kahan 2001 Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations J Am Soc Nephrol 12 1059 1071 (Pubitemid 32378348)
14. D Anglicheau N Pallet M Rabant P Marquet B Cassinat P Meria P Beaune C Legendre E Thervet 2006 Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction Kidney Int 70 1019 1025 (Pubitemid 44344071)
15. RS Hotchkiss SB Osmon KC Chang TH Wagner CM Coopersmith IE Karl 2005 Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways J Immunol 174 5110 5118
16. AG Barbari MA Masri AG Stephan B El Ghoul S Rizk N Mourad GS Kamel HE Kilani AS Karam 2006 Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study Exp Clin Transplant 4 400 405 (Pubitemid 43984095)
17. P Falck A Asberg H Guldseth S Bremer F Akhlaghi JL Reubsaet P Pfeffer A Hartmann K Midtvedt 2008 Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients Transplantation 85 179 184 (Pubitemid 351156847)
18. V Mardigyan N Giannetti R Cecere JG Besner M Cantarovich 2005 Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus J Heart Lung Transplant 24 1614 1618 (Pubitemid 41396461)
19. RJ Farrell MJ Menconi AC Keates CP Kelly 2002 P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes Aliment Pharmacol Ther 16 1021 1031 (Pubitemid 34461774)
20. A Laplante M Demeule GF Murphy R Beliveau 2002 Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp Transplant Proc 34 3393 3395 (Pubitemid 35463353)
21. N Serkova B Hausen GJ Berry W Jacobsen LZ Benet RE Morris U Christians 2000 Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine J Pharmacol Exp Ther 294 323 332 (Pubitemid 30434704)
22. AC Rodrigues R Curi LR Britto IM Rebbechi MH Hirata MC Bertolami MM Bernik EL Dorea RD Hirata 2006 Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells Biochim Biophys Acta 1760 1866 1873 (Pubitemid 44692371)
23. S Crettol JP Venetz M Fontana JD Aubert N Ansermot M Fathi M Pascual CB Eap 2008 Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients Pharmacogenet Genomics 18 307 315
24. VS Donnenberg GJ Burckart A Zeevi BP Griffith A Iacono KR McCurry JW Wilson AD Donnenberg 2004 P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection Transplantation 77 1699 1706 (Pubitemid 38780536)